<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药明康德 | wechat-feeds</title><link>http://MzAwMDA5NTIxNQ.favicon.privacyhide.com/favicon.ico</link><description>全球领先的制药、生物技术以及医疗器械研发开放式能力和技术平台，帮助任何人、任何公司更快、更好地研发新医药产品，探索无限可能</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 08 Mar 2021 14:17:12 +0800</pubDate><image><url>http://MzAwMDA5NTIxNQ.favicon.privacyhide.com/favicon.ico</url><title>药明康德 | wechat-feeds</title><link>http://MzAwMDA5NTIxNQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>药明康德宣布完成对OXGENE的收购，持续加强细胞和基因疗法全球服务能力 | Bilingual News</title><link>https://mp.weixin.qq.com/s/U1hME3TXGz27lD2BG7X8OQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gO1L7YJfaQvr5wSibmOHyHFwmOcXyslicdcRIvejicOMtHX7w6shb32ibicIEWAic4O3qZTDYEtdNGIkngg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>WuXi AppTec Completes Acquisition of OXGENE]]></content:encoded><pubDate>Tue, 02 Mar 2021 20:10:58 +0800</pubDate></item><item><title>成功靶向两大“不可成药”靶点，双特异性抗体研究再获突破！</title><link>https://mp.weixin.qq.com/s/XFsMa-doUTeJi66n_ZU1xw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gO1L7YJfaQvr5wSibmOHyHFw7efSgPskNra5qL50OH2AmwyKmF2hHNqTeZRX712UUoJTWLT1KicYTMA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>靶向p53和RAS]]></content:encoded><pubDate>Tue, 02 Mar 2021 20:10:58 +0800</pubDate></item><item><title>速递 | 约10亿美元囊获突破性头颈癌疗法，德国默克达成许可协议</title><link>https://mp.weixin.qq.com/s/L5Z0pJm9PpZEy0OGJ4purg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gO1L7YJfaQvr5wSibmOHyHFwYC22AA0xIzoknAHCeY797HFjq3yS1cBOuQsq4uuOup7CldxUvTiaPLA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>潜在“first-in-class”凋亡蛋白抑制剂的口服拮抗剂]]></content:encoded><pubDate>Tue, 02 Mar 2021 20:10:58 +0800</pubDate></item><item><title>速递 | 结合抗体和小分子药物的优点，新锐获1.07亿美元助力开发创新药物类型</title><link>https://mp.weixin.qq.com/s/iBOzk0-6PZ6973XrMeN8cg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gO1L7YJfaQvr5wSibmOHyHFw4MTT3JhJj64Sv0Jz6ib1H32hPss2vmJribJy3Gd0BtsWTZrzxSK0kSzQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>几乎可以靶向所有靶点]]></content:encoded><pubDate>Tue, 02 Mar 2021 20:10:58 +0800</pubDate></item><item><title>首款抗癌肽偶联药物新近获批，肽偶联技术平台前景如何？</title><link>https://mp.weixin.qq.com/s/0vOxYlT2HoHTZtezRq_juw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gO1L7YJfaQvr5wSibmOHyHFwffhhtntibrzyP4T9gD2kbbP2qfEdc1DFqWauTBib0hcicrp9ZjYslnR8w/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>综述多肽类药物的优点和局限性，及其应用于PDC靶向治疗癌症的最新趋势]]></content:encoded><pubDate>Tue, 02 Mar 2021 20:10:58 +0800</pubDate></item><item><title>少吃点糖吧！不止是发胖，糖浆还让免疫系统很受伤……</title><link>https://mp.weixin.qq.com/s/6aSOhMWID0nQyF338UEyWA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gO1L7YJfaQvr5wSibmOHyHFwIkP7mic1fSZC0h7KmE9WSsxSvpibNHr9OI6ic3iaObdm6EJFOZGeAv1crw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>进一步理解为什么有些饮食方式会有损健康]]></content:encoded><pubDate>Tue, 02 Mar 2021 20:10:58 +0800</pubDate></item><item><title>增强抗PD-1/PD-L1疗法效力，蛋白降解成为新兴策略？</title><link>https://mp.weixin.qq.com/s/sS52PPsFR5z0mclCtOEvrQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gO1bODoX0ibtQmBicSz7Lj7TQbWYZFFpfUtLx9NHwVaoIA5WSUGLtP7f5zjlgVM0sH4Dl3Nur8vcUAg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>降解PD-1/PD-L1的多种途径]]></content:encoded><pubDate>Mon, 01 Mar 2021 07:37:08 +0800</pubDate></item><item><title>速递 | “first-in-class”肽偶联药物获FDA加速批准，治疗多发性骨髓瘤</title><link>https://mp.weixin.qq.com/s/oDbA_C6IKZeR8Z4QuoNG4Q</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gO1bODoX0ibtQmBicSz7Lj7TQbSnJEicretz6ZHccVzKOl74dLbWusBibZsGI7vZtibuH1DgnaEKpqqtVA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药明康德]]></content:encoded><pubDate>Mon, 01 Mar 2021 07:37:08 +0800</pubDate></item><item><title>强生单剂新冠疫苗获FDA紧急使用授权</title><link>https://mp.weixin.qq.com/s/UKJVGOMYDQM_qi1PyXeAaw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gO1bODoX0ibtQmBicSz7Lj7TQic5b00Ps9MpfKSGrEqCDy9KykLRe1DiaXebRhSLZicWtZ1t6ZCnAPjP8A/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药明康德]]></content:encoded><pubDate>Mon, 01 Mar 2021 07:37:08 +0800</pubDate></item><item><title>孤儿药周报 | 百时美施贵宝BMCA抗体偶联药物、康方生物PD-1单克隆抗体等入围</title><link>https://mp.weixin.qq.com/s/IGP8nFMPa_XlPUcjD20Ocg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gO1bODoX0ibtQmBicSz7Lj7TQXS3mUojhicBib7cczMqE9WicTfNt19EPDicicqrY8SfxM20iaxc1RYibDXE5g/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药明康德]]></content:encoded><pubDate>Mon, 01 Mar 2021 07:37:08 +0800</pubDate></item><item><title>艾伯维JAK抑制剂达到3期临床终点；默沙东18.5亿美元拓展自身免疫疾病研发管线</title><link>https://mp.weixin.qq.com/s/zlHHNoRJDI_OFga7drC2Gw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gNgqG1xzIhbHQL4aJ8o6JWib3hXsUx6z3jczUN8OadRne8FKLR1guhUicNGKIsTgSZnibYa3lWeb571A/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>行业一周新闻回顾]]></content:encoded><pubDate>Mon, 01 Mar 2021 07:37:08 +0800</pubDate></item><item><title>明日下午3点！灵活多样质粒工艺开发平台，推动细胞基因治疗研发进程</title><link>https://mp.weixin.qq.com/s/2QweVMvWFiT7lNyo1dy_Hw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gO1bODoX0ibtQmBicSz7Lj7TQiapTUHI6vpD5lC0usM4b6YZjdEr6Yfy8iblAKN2xd7PL95ibYHicK7BCBA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>基因治疗系列（三）]]></content:encoded><pubDate>Mon, 01 Mar 2021 07:37:08 +0800</pubDate></item><item><title>2020年获批罕见病疗法中有哪些“第一”？| 国际罕见病日</title><link>https://mp.weixin.qq.com/s/14eOTZPr70LUg7TYzPYu2w</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gObHx0odUDfFnESbRP1UTVr5urcOJoSzUUOSObiaDaBrFib3y2cCoDWBcIIf6WgYeCRicMrrSdZa2VEA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药明康德]]></content:encoded><pubDate>Sat, 27 Feb 2021 08:06:13 +0800</pubDate></item><item><title>罕见病专栏 | 一周罕闻药事（2.16-2.25）</title><link>https://mp.weixin.qq.com/s/k8oKwnD5dTjZoPeDjAOpCg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gNDMeJZiaFaqUv0lLceQMa9ty1gibZQWibPicficre59nB0wZjJib5kdHo18yicQHGq9Se99gJ6KCvafYW2A/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>罕闻药事，为您汇总罕见病研发领域最新资讯]]></content:encoded><pubDate>Sat, 27 Feb 2021 08:06:13 +0800</pubDate></item><item><title>速递 | 22：0！强生单剂新冠疫苗获咨询委员会全票支持</title><link>https://mp.weixin.qq.com/s/b_XkFcLwyulCd6WVTAuYWg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gObHx0odUDfFnESbRP1UTVrK7q9TARwdmAmHg0TEYIGaibuib04DPsuJibcg6FCchNoaKP9SiaNFyL8GA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>有望明日获FDA紧急使用授权]]></content:encoded><pubDate>Sat, 27 Feb 2021 08:06:13 +0800</pubDate></item><item><title>速递 | 降低疾病加重率56%，潜在“first-in-class”抗体疗法达到所有3期主要终点</title><link>https://mp.weixin.qq.com/s/EHVAoi1Jqkc3q02L1WriTA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gObHx0odUDfFnESbRP1UTVrNHfgWmia6NVe7cSzEMJhRNXoApkP3FICe8Cee4hCZEk4ThdicOwHGsDg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>在广泛重度哮喘患者人群中一致性降低疾病加重率]]></content:encoded><pubDate>Sat, 27 Feb 2021 08:06:13 +0800</pubDate></item><item><title>速递 | 治疗致命儿童代谢缺陷，FDA今日批准首款疗法</title><link>https://mp.weixin.qq.com/s/9rMXpx-nA93yozhFttYxnA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gObHx0odUDfFnESbRP1UTVrZvDsfAiaAx4oPCJftlXyU32xKv9uhjWpvuz2ZS6wGU65fHic5ibAkEcGg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药明康德]]></content:encoded><pubDate>Sat, 27 Feb 2021 08:06:13 +0800</pubDate></item><item><title>FDA今日加速批准DMD疗法上市，还有这些疗法值得患者期待</title><link>https://mp.weixin.qq.com/s/15P38SGf1BPOD6G2KJzUVg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gMPyY57lJol1L1O0hJbicfMibOgrib0s1fGEL78lfcCpeRYKRa8INrDQgTmlvVSWMoiaCSmyFHbic3IdRw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药明康德]]></content:encoded><pubDate>Fri, 26 Feb 2021 08:11:53 +0800</pubDate></item><item><title>新冠疗法临床试验中只有5%能够给出指导性结果？FDA代理局长联名发文</title><link>https://mp.weixin.qq.com/s/8pgjgrAr0UIQwX7oqcTR8Q</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gMPyY57lJol1L1O0hJbicfMibXiaict6IlcU8m1D8058rgEbloiaUeWJDpNeia4XE7icfHZNGahiamIM6TF8Q/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药明康德]]></content:encoded><pubDate>Fri, 26 Feb 2021 08:11:53 +0800</pubDate></item><item><title>速递 | 18.5亿美元拓展自身免疫疾病研发管线，默沙东囊获IL-2靶向疗法</title><link>https://mp.weixin.qq.com/s/loZwTFxb0OH2xCEy3tS0LQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gMPyY57lJol1L1O0hJbicfMibZvuwu1jft3PupLguia2rCRvnSfic4lw5EdPC7Y0EG0ibHmpdnAIDGM4YQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>特异性激活调节性T细胞]]></content:encoded><pubDate>Fri, 26 Feb 2021 08:11:53 +0800</pubDate></item></channel></rss>